Amprenavir vs Tipranavir

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV protease · full HIV pipeline

Amprenavir

Rights held by GlaxoSmithKline; US product discontinued

Approved in HIVsmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Tipranavir · Aptivus

Marketed by Boehringer Ingelheim

Approved in HIVsmall molecule
Partial signal

NCT00144170 · Phase 3 · completed

The trial randomized participants to an active comparator and included 882 enrolled participants, with 863 in the reported efficacy denominators, but the registry does not clearly report masking. Both primary virologic endpoints favored tipranavir with statistically significant comparisons; however, the primary outcomes were virologic surrogate measures rather than hard clinical outcomes, so the evidence is rated moderate.

Reported efficacy

Treatment Response at Week 48 (after 48 weeks of treatment); Time to Treatment Failure Through 48 Weeks of Treatment (after 48 weeks of treatment): Treatment Response at Week 48 (after 48 weeks of treatment): Tipranavir(TPV)/Low Dose Ritonavir(r) 34.5% vs Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r) 15% (met)

Result source: NCT00144170

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAmprenavirTipranavir
HIV-1 RNA below 50 copies/mL (week 48)—Not posted · NCT00002195—Not reported
HIV-1 RNA 50 copies/mL or more (week 48)—Not posted · NCT00002195—Not reported
CD4 count, change (week 48)—Not posted · NCT0000219541 vs 20vs Comparator Protease Inhibitorwk 96 · n 430NCT00144170
19 other results
  • 60 vs 28 wk 96 · n 311 · Phase 3 · secondary NCT00054717
  • 41 vs 19 wk 88 · n 430 · Phase 3 · secondary NCT00144170
  • 60 vs 29 wk 88 · n 311 · Phase 3 · secondary NCT00054717
  • 39 vs 19 wk 80 · n 430 · Phase 3 · secondary NCT00144170
  • 55 vs 26 wk 80 · n 311 · Phase 3 · secondary NCT00054717
  • 42 vs 18 wk 72 · n 430 · Phase 3 · secondary NCT00144170
  • 50 vs 24 wk 72 · n 311 · Phase 3 · secondary NCT00054717
  • 42 vs 13 wk 64 · n 430 · Phase 3 · secondary NCT00144170
  • 50 vs 26 wk 64 · n 311 · Phase 3 · secondary NCT00054717
  • 39 vs 16 wk 56 · n 430 · Phase 3 · secondary NCT00144170
  • 52 vs 26 wk 56 · n 311 · Phase 3 · secondary NCT00054717
  • 43 vs 16 wk 48 · n 430 · Phase 3 · secondary NCT00144170
  • 46 vs 28 wk 48 · n 311 · Phase 3 · secondary NCT00054717
  • 47 vs 19 wk 40 · n 430 · Phase 3 · secondary NCT00144170
  • 50 vs 24 wk 40 · n 311 · Phase 3 · secondary NCT00054717
  • 46 vs 17 wk 32 · n 430 · Phase 3 · secondary NCT00144170
  • 51 vs 26 wk 32 · n 311 · Phase 3 · secondary NCT00054717
  • 51 vs 21 wk 24 · n 430 · Phase 3 · secondary NCT00144170
  • 54 vs 24 wk 24 · n 311 · Phase 3 · secondary NCT00054717

HIV-1 RNA below 50 copies/mL (week 48)

Amprenavir
—Not posted · NCT00002195
Tipranavir
—Not reported

HIV-1 RNA 50 copies/mL or more (week 48)

Amprenavir
—Not posted · NCT00002195
Tipranavir
—Not reported

CD4 count, change (week 48)

Amprenavir
—Not posted · NCT00002195
Tipranavir
41 vs 20vs Comparator Protease Inhibitorwk 96 · n 430NCT00144170
19 other results
  • 60 vs 28 wk 96 · n 311 · Phase 3 · secondary NCT00054717
  • 41 vs 19 wk 88 · n 430 · Phase 3 · secondary NCT00144170
  • 60 vs 29 wk 88 · n 311 · Phase 3 · secondary NCT00054717
  • 39 vs 19 wk 80 · n 430 · Phase 3 · secondary NCT00144170
  • 55 vs 26 wk 80 · n 311 · Phase 3 · secondary NCT00054717
  • 42 vs 18 wk 72 · n 430 · Phase 3 · secondary NCT00144170
  • 50 vs 24 wk 72 · n 311 · Phase 3 · secondary NCT00054717
  • 42 vs 13 wk 64 · n 430 · Phase 3 · secondary NCT00144170
  • 50 vs 26 wk 64 · n 311 · Phase 3 · secondary NCT00054717
  • 39 vs 16 wk 56 · n 430 · Phase 3 · secondary NCT00144170
  • 52 vs 26 wk 56 · n 311 · Phase 3 · secondary NCT00054717
  • 43 vs 16 wk 48 · n 430 · Phase 3 · secondary NCT00144170
  • 46 vs 28 wk 48 · n 311 · Phase 3 · secondary NCT00054717
  • 47 vs 19 wk 40 · n 430 · Phase 3 · secondary NCT00144170
  • 50 vs 24 wk 40 · n 311 · Phase 3 · secondary NCT00054717
  • 46 vs 17 wk 32 · n 430 · Phase 3 · secondary NCT00144170
  • 51 vs 26 wk 32 · n 311 · Phase 3 · secondary NCT00054717
  • 51 vs 21 wk 24 · n 430 · Phase 3 · secondary NCT00144170
  • 54 vs 24 wk 24 · n 311 · Phase 3 · secondary NCT00054717
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Amprenavir: no structured comparison results are available for HIV.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Amprenavir: 0 of 4 rows · Tipranavir: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricTipranavir
Dropout rate
80.4%
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
show 1 more result
83.7%
NCT00054717 · Phase 3 · combination · HIV · phase 3
Discontinued due to AEs
19.2%
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
show 1 more result
22.4%
NCT00054717 · Phase 3 · combination · HIV · phase 3
Serious AEs
28.1%
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
show 1 more result
36.3%
NCT00054717 · Phase 3 · combination · HIV · phase 3
Most frequent reported AEs
diarrhoea 33.8%
nausea 19.9%
headache 17.8%
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
show 1 more result
diarrhoea 39.5%
nausea 28.3%
fatigue 22.8%
NCT00054717 · Phase 3 · combination · HIV · phase 3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Tipranavir

Virologic 34.5% (n=435) vs 15% (n=428) Comparator Protease Inhibitor @ 48wk
responder rate · % of participants
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
show 58 more results
51% (n=435) vs 25.9% (n=428) Comparator Protease Inhibitor @ 2wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
59.1% (n=435) vs 29.9% (n=428) Comparator Protease Inhibitor @ 4wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
54.3% (n=435) vs 24.5% (n=428) Comparator Protease Inhibitor @ 8wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
47.1% (n=435) vs 19.9% (n=428) Comparator Protease Inhibitor @ 16wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
40.9% (n=435) vs 18% (n=428) Comparator Protease Inhibitor @ 24wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
37.2% (n=435) vs 17.3% (n=428) Comparator Protease Inhibitor @ 32wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
36.3% (n=435) vs 16.6% (n=428) Comparator Protease Inhibitor @ 40wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
32.6% (n=435) vs 14.5% (n=428) Comparator Protease Inhibitor @ 56wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
31% (n=435) vs 13.3% (n=428) Comparator Protease Inhibitor @ 64wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
30.1% (n=435) vs 12.1% (n=428) Comparator Protease Inhibitor @ 72wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
28.5% (n=435) vs 11.4% (n=428) Comparator Protease Inhibitor @ 80wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
27.8% (n=435) vs 11% (n=428) Comparator Protease Inhibitor @ 88wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
26.2% (n=435) vs 10% (n=428) Comparator Protease Inhibitor @ 96wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
75.6% (n=435) vs 48.6% (n=428) Comparator Protease Inhibitor
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
60.5% (n=435) vs 36% (n=428) Comparator Protease Inhibitor @ 2wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
62.3% (n=435) vs 33.4% (n=428) Comparator Protease Inhibitor @ 4wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
56.3% (n=435) vs 26.6% (n=428) Comparator Protease Inhibitor @ 8wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
47.1% (n=435) vs 20.8% (n=428) Comparator Protease Inhibitor @ 16wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
42.8% (n=435) vs 19.2% (n=428) Comparator Protease Inhibitor @ 24wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
38.6% (n=435) vs 19.4% (n=428) Comparator Protease Inhibitor @ 32wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
37% (n=435) vs 17.3% (n=428) Comparator Protease Inhibitor @ 40wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
36.8% (n=435) vs 16.6% (n=428) Comparator Protease Inhibitor @ 48wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
35.2% (n=435) vs 15.2% (n=428) Comparator Protease Inhibitor @ 56wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
33.6% (n=435) vs 14% (n=428) Comparator Protease Inhibitor @ 64wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
32.2% (n=435) vs 13.8% (n=428) Comparator Protease Inhibitor @ 72wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
32.6% (n=435) vs 13.6% (n=428) Comparator Protease Inhibitor @ 80wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
31% (n=435) vs 12.1% (n=428) Comparator Protease Inhibitor @ 88wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
30.1% (n=435) vs 11.4% (n=428) Comparator Protease Inhibitor @ 96wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
31.5% (n=435) vs 15% (n=428) Comparator Protease Inhibitor @ 40wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
52.2% (n=435) vs 25.7% (n=428) Comparator Protease Inhibitor
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
14.5% (n=435) vs 8.2% (n=428) Comparator Protease Inhibitor @ 2wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
26.2% (n=435) vs 15.2% (n=428) Comparator Protease Inhibitor @ 4wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
33.3% (n=435) vs 17.5% (n=428) Comparator Protease Inhibitor @ 8wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
35.2% (n=435) vs 17.5% (n=428) Comparator Protease Inhibitor @ 16wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
32.6% (n=435) vs 15.4% (n=428) Comparator Protease Inhibitor @ 24wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
32.4% (n=435) vs 16.1% (n=428) Comparator Protease Inhibitor @ 32wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
30.1% (n=435) vs 13.6% (n=428) Comparator Protease Inhibitor @ 48wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
30.6% (n=435) vs 12.4% (n=428) Comparator Protease Inhibitor @ 56wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
28.7% (n=435) vs 12.1% (n=428) Comparator Protease Inhibitor @ 64wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
28% (n=435) vs 11.4% (n=428) Comparator Protease Inhibitor @ 72wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
28.7% (n=435) vs 11% (n=428) Comparator Protease Inhibitor @ 80wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
27.8% (n=435) vs 11.2% (n=428) Comparator Protease Inhibitor @ 88wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
27.1% (n=435) vs 10.3% (n=428) Comparator Protease Inhibitor @ 96wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
36.6% (n=435) vs 16.8% (n=428) Comparator Protease Inhibitor
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
0.9% (n=435) vs 1.4% (n=428) Comparator Protease Inhibitor @ 2wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
4.4% (n=435) vs 3.5% (n=428) Comparator Protease Inhibitor @ 4wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
11% (n=435) vs 6.8% (n=428) Comparator Protease Inhibitor @ 8wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
20.5% (n=435) vs 10.5% (n=428) Comparator Protease Inhibitor @ 16wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
21.1% (n=435) vs 11.9% (n=428) Comparator Protease Inhibitor @ 24wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
22.1% (n=435) vs 12.1% (n=428) Comparator Protease Inhibitor @ 32wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
22.3% (n=435) vs 11.9% (n=428) Comparator Protease Inhibitor @ 40wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
22.8% (n=435) vs 10.5% (n=428) Comparator Protease Inhibitor @ 48wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
22.5% (n=435) vs 8.9% (n=428) Comparator Protease Inhibitor @ 56wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
21.6% (n=435) vs 8.2% (n=428) Comparator Protease Inhibitor @ 64wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
21.1% (n=435) vs 8.2% (n=428) Comparator Protease Inhibitor @ 72wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
21.8% (n=435) vs 8.9% (n=428) Comparator Protease Inhibitor @ 80wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
20.7% (n=435) vs 8.9% (n=428) Comparator Protease Inhibitor @ 88wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
20% (n=435) vs 8.9% (n=428) Comparator Protease Inhibitor @ 96wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
Time to Treatment Failure 3.68 vs 0 Comparator Protease Inhibitor months @ 48wk
time to event · months
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3 · converted to months from 112 days as posted
show 3 more results
3.78 vs 0 Comparator Protease Inhibitor months @ 96wk*
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3 · converted to months from 115 days as posted
3.71 vs 0 Comparitor Protease Inhibitor(CPR) months @ 48wk*
NCT00054717 · Phase 3 · combination · HIV · phase 3 · converted to months from 113 days as posted
3.75 vs 0 Comparitor Protease Inhibitor(CPR) months @ 96wk*
NCT00054717 · Phase 3 · combination · HIV · phase 3 · converted to months from 114 days as posted
Time to Confirmed Virologic Failure 3.84 vs 0 Comparator Protease Inhibitor months @ 48wk
time to event · months
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3 · converted to months from 117 days as posted
show 3 more results
3.84 vs 0 Comparator Protease Inhibitor months @ 96wk*
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3 · converted to months from 117 days as posted
3.71 vs 0 Comparitor Protease Inhibitor(CPR) months @ 48wk*
NCT00054717 · Phase 3 · combination · HIV · phase 3 · converted to months from 113 days as posted
3.81 vs 0 Comparitor Protease Inhibitor(CPR) months @ 96wk*
NCT00054717 · Phase 3 · combination · HIV · phase 3 · converted to months from 116 days as posted
HIV-1 RNA -1.27 vs -0.56 Comparator Protease Inhibitor copies/mL @ 2wk
absolute change · copies/mL
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
show 27 more results
-1.47 vs -0.42 Comparator Protease Inhibitor copies/mL @ 4wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
-1.4 vs -0.33 Comparator Protease Inhibitor copies/mL @ 8wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
-1.03 vs -0.3 Comparator Protease Inhibitor copies/mL @ 16wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
-0.69 vs -0.21 Comparator Protease Inhibitor copies/mL @ 24wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
-0.63 vs -0.24 Comparator Protease Inhibitor copies/mL @ 32wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
-0.65 vs -0.2 Comparator Protease Inhibitor copies/mL @ 40wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
-0.65 vs -0.2 Comparator Protease Inhibitor copies/mL @ 48wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
-0.64 vs -0.22 Comparator Protease Inhibitor copies/mL @ 56wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
-0.63 vs -0.21 Comparator Protease Inhibitor copies/mL @ 64wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
-0.52 vs -0.2 Comparator Protease Inhibitor copies/mL @ 72wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
-0.55 vs -0.2 Comparator Protease Inhibitor copies/mL @ 80wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
-0.56 vs -0.2 Comparator Protease Inhibitor copies/mL @ 88wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
-0.56 vs -0.2 Comparator Protease Inhibitor copies/mL @ 96wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
-1.36 vs -0.57 Comparitor Protease Inhibitor(CPR) copies/mL @ 2wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
-1.56 vs -0.46 Comparitor Protease Inhibitor(CPR) copies/mL @ 4wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
-1.6 vs -0.43 Comparitor Protease Inhibitor(CPR) copies/mL @ 8wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
-1.08 vs -0.32 Comparitor Protease Inhibitor(CPR) copies/mL @ 16wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
-0.81 vs -0.3 Comparitor Protease Inhibitor(CPR) copies/mL @ 24wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
-0.73 vs -0.24 Comparitor Protease Inhibitor(CPR) copies/mL @ 32wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
-0.74 vs -0.23 Comparitor Protease Inhibitor(CPR) copies/mL @ 40wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
-0.61 vs -0.24 Comparitor Protease Inhibitor(CPR) copies/mL @ 48wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
-0.57 vs -0.23 Comparitor Protease Inhibitor(CPR) copies/mL @ 56wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
-0.6 vs -0.23 Comparitor Protease Inhibitor(CPR) copies/mL @ 64wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
-0.65 vs -0.21 Comparitor Protease Inhibitor(CPR) copies/mL @ 72wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
-0.64 vs -0.21 Comparitor Protease Inhibitor(CPR) copies/mL @ 80wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
-0.64 vs -0.21 Comparitor Protease Inhibitor(CPR) copies/mL @ 88wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
-0.6 vs -0.21 Comparitor Protease Inhibitor(CPR) copies/mL @ 96wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
CD4+ 26 vs 13 Comparator Protease Inhibitor cells/uL @ 2wk
absolute change · cells/uL
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
show 27 more results
39 vs 19 Comparator Protease Inhibitor cells/uL @ 4wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
52 vs 25 Comparator Protease Inhibitor cells/uL @ 8wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
57 vs 25 Comparator Protease Inhibitor cells/uL @ 16wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
51 vs 21 Comparator Protease Inhibitor cells/uL @ 24wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
46 vs 17 Comparator Protease Inhibitor cells/uL @ 32wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
47 vs 19 Comparator Protease Inhibitor cells/uL @ 40wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
43 vs 16 Comparator Protease Inhibitor cells/uL @ 48wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
39 vs 16 Comparator Protease Inhibitor cells/uL @ 56wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
42 vs 13 Comparator Protease Inhibitor cells/uL @ 64wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
42 vs 18 Comparator Protease Inhibitor cells/uL @ 72wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
39 vs 19 Comparator Protease Inhibitor cells/uL @ 80wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
41 vs 19 Comparator Protease Inhibitor cells/uL @ 88wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
41 vs 20 Comparator Protease Inhibitor cells/uL @ 96wk
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3
23 vs 19 Comparitor Protease Inhibitor(CPR) cells/uL @ 2wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
41 vs 22 Comparitor Protease Inhibitor(CPR) cells/uL @ 4wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
49 vs 25 Comparitor Protease Inhibitor(CPR) cells/uL @ 8wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
55 vs 30 Comparitor Protease Inhibitor(CPR) cells/uL @ 16wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
54 vs 24 Comparitor Protease Inhibitor(CPR) cells/uL @ 24wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
51 vs 26 Comparitor Protease Inhibitor(CPR) cells/uL @ 32wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
50 vs 24 Comparitor Protease Inhibitor(CPR) cells/uL @ 40wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
46 vs 28 Comparitor Protease Inhibitor(CPR) cells/uL @ 48wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
52 vs 26 Comparitor Protease Inhibitor(CPR) cells/uL @ 56wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
50 vs 26 Comparitor Protease Inhibitor(CPR) cells/uL @ 64wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
50 vs 24 Comparitor Protease Inhibitor(CPR) cells/uL @ 72wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
55 vs 26 Comparitor Protease Inhibitor(CPR) cells/uL @ 80wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
60 vs 29 Comparitor Protease Inhibitor(CPR) cells/uL @ 88wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
60 vs 28 Comparitor Protease Inhibitor(CPR) cells/uL @ 96wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
Time to CDC Class C Event or Death 17.35 vs 10.91 Comparator Protease Inhibitor months @ 75wk
time to event · months
NCT00144170 · Phase 3 · monotherapy · HIV · phase 3 · converted to months from 528 days as posted
show 1 more result
14.72 vs 9.33 Comparitor Protease Inhibitor(CPR) months*
NCT00054717 · Phase 3 · combination · HIV · phase 3 · converted to months from 448 days as posted
Virologic Response 1 Log Drop 33.8% (n=311) vs 16.2% (n=309) Comparitor Protease Inhibitor(CPR) @ 48wk
responder rate · % of participants
NCT00054717 · Phase 3 · combination · HIV · phase 3
show 26 more results
41.8% (n=311) vs 23.9% (n=309) Comparitor Protease Inhibitor(CPR) @ 24wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
53.1% (n=311) vs 34.3% (n=309) Comparitor Protease Inhibitor(CPR) @ 2wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
52.4% (n=311) vs 33.3% (n=309) Comparitor Protease Inhibitor(CPR) @ 4wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
52.4% (n=311) vs 33.3% (n=309) Comparitor Protease Inhibitor(CPR) @ 8wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
45.7% (n=311) vs 27.5% (n=309) Comparitor Protease Inhibitor(CPR) @ 16wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
42.1% (n=311) vs 23.6% (n=309) Comparitor Protease Inhibitor(CPR) @ 24wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
37.9% (n=311) vs 19.4% (n=309) Comparitor Protease Inhibitor(CPR) @ 32wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
35.4% (n=311) vs 17.8% (n=309) Comparitor Protease Inhibitor(CPR) @ 40wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
33.8% (n=311) vs 16.2% (n=309) Comparitor Protease Inhibitor(CPR) @ 48wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
32.5% (n=311) vs 15.9% (n=309) Comparitor Protease Inhibitor(CPR) @ 56wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
31.3% (n=311) vs 15.5% (n=309) Comparitor Protease Inhibitor(CPR) @ 64wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
29.6% (n=311) vs 14.9% (n=309) Comparitor Protease Inhibitor(CPR) @ 72wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
28% (n=311) vs 14.2% (n=309) Comparitor Protease Inhibitor(CPR) @ 80wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
27.3% (n=311) vs 12.9% (n=309) Comparitor Protease Inhibitor(CPR) @ 88wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
26.7% (n=311) vs 11.7% (n=309) Comparitor Protease Inhibitor(CPR) @ 96wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
79.1% (n=311) vs 50.5% (n=309) Comparitor Protease Inhibitor(CPR)
NCT00054717 · Phase 3 · combination · HIV · phase 3
63.3% (n=311) vs 40.1% (n=309) Comparitor Protease Inhibitor(CPR) @ 2wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
63.3% (n=311) vs 40.1% (n=309) Comparitor Protease Inhibitor(CPR) @ 4wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
55.9% (n=311) vs 34.3% (n=309) Comparitor Protease Inhibitor(CPR) @ 8wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
47.3% (n=311) vs 26.5% (n=309) Comparitor Protease Inhibitor(CPR) @ 16wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
43.1% (n=311) vs 22.3% (n=309) Comparitor Protease Inhibitor(CPR) @ 24wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
38.9% (n=311) vs 19.1% (n=309) Comparitor Protease Inhibitor(CPR) @ 32wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
36.7% (n=311) vs 17.5% (n=309) Comparitor Protease Inhibitor(CPR) @ 40wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
36.3% (n=311) vs 16.2% (n=309) Comparitor Protease Inhibitor(CPR) @ 48wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
34.1% (n=311) vs 15.5% (n=309) Comparitor Protease Inhibitor(CPR) @ 56wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
34.1% (n=311) vs 16.2% (n=309) Comparitor Protease Inhibitor(CPR) @ 64wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
Virologic Response Lt400 53.4% (n=311) vs 32.4% (n=309) Comparitor Protease Inhibitor(CPR)
responder rate · % of participants
NCT00054717 · Phase 3 · combination · HIV · phase 3
show 14 more results
14.8% (n=311) vs 13.6% (n=309) Comparitor Protease Inhibitor(CPR) @ 2wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
28.3% (n=311) vs 19.1% (n=309) Comparitor Protease Inhibitor(CPR) @ 4wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
37.3% (n=311) vs 23.6% (n=309) Comparitor Protease Inhibitor(CPR) @ 8wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
35.7% (n=311) vs 20.7% (n=309) Comparitor Protease Inhibitor(CPR) @ 16wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
34.4% (n=311) vs 16.5% (n=309) Comparitor Protease Inhibitor(CPR) @ 24wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
32.8% (n=311) vs 14.9% (n=309) Comparitor Protease Inhibitor(CPR) @ 32wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
32.8% (n=311) vs 14.6% (n=309) Comparitor Protease Inhibitor(CPR) @ 40wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
30.5% (n=311) vs 13.6% (n=309) Comparitor Protease Inhibitor(CPR) @ 48wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
29.6% (n=311) vs 13.9% (n=309) Comparitor Protease Inhibitor(CPR) @ 56wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
28.6% (n=311) vs 13.3% (n=309) Comparitor Protease Inhibitor(CPR) @ 64wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
28.9% (n=311) vs 12.9% (n=309) Comparitor Protease Inhibitor(CPR) @ 72wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
27.7% (n=311) vs 13.6% (n=309) Comparitor Protease Inhibitor(CPR) @ 80wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
27.7% (n=311) vs 12.6% (n=309) Comparitor Protease Inhibitor(CPR) @ 88wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
26.7% (n=311) vs 11.7% (n=309) Comparitor Protease Inhibitor(CPR) @ 96wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
Virologic Response Lt50 37.9% (n=311) vs 20.4% (n=309) Comparitor Protease Inhibitor(CPR)
responder rate · % of participants
NCT00054717 · Phase 3 · combination · HIV · phase 3
show 14 more results
1.9% (n=311) vs 1.9% (n=309) Comparitor Protease Inhibitor(CPR) @ 2wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
6.4% (n=311) vs 4.2% (n=309) Comparitor Protease Inhibitor(CPR) @ 4wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
16.1% (n=311) vs 8.1% (n=309) Comparitor Protease Inhibitor(CPR) @ 8wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
23.5% (n=311) vs 9.4% (n=309) Comparitor Protease Inhibitor(CPR) @ 16wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
24.8% (n=311) vs 10% (n=309) Comparitor Protease Inhibitor(CPR) @ 24wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
24.8% (n=311) vs 10% (n=309) Comparitor Protease Inhibitor(CPR) @ 32wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
23.5% (n=311) vs 8.4% (n=309) Comparitor Protease Inhibitor(CPR) @ 40wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
22.5% (n=311) vs 9.7% (n=309) Comparitor Protease Inhibitor(CPR) @ 48wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
21.5% (n=311) vs 10% (n=309) Comparitor Protease Inhibitor(CPR) @ 56wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
22.8% (n=311) vs 10.7% (n=309) Comparitor Protease Inhibitor(CPR) @ 64wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
21.2% (n=311) vs 11.3% (n=309) Comparitor Protease Inhibitor(CPR) @ 72wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
20.6% (n=311) vs 10.7% (n=309) Comparitor Protease Inhibitor(CPR) @ 80wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
22.2% (n=311) vs 9.7% (n=309) Comparitor Protease Inhibitor(CPR) @ 88wk
NCT00054717 · Phase 3 · combination · HIV · phase 3
20.9% (n=311) vs 9.4% (n=309) Comparitor Protease Inhibitor(CPR) @ 96wk
NCT00054717 · Phase 3 · combination · HIV · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Amprenavir's landscape · Tipranavir's landscape